Related Experiment Videos
[The development from drug to designer drug]
Bjarke Askaa1, Henrik Horwitz, Vidar André Wøien
1Klinisk Farmakologisk Afdeling, Bispebjerg -Hospital, Bispebjerg Bakke 23, 2400 København NV. bjarke.askaa.03@regionh.dk.
Ugeskrift for Laeger
|October 16, 2014
Summary
New designer drugs with hallucinogenic effects are emerging, often derived from medications for depression. This review examines clinical symptoms and treatment for intoxication from these substances, based on literature and poison center data.
Area of Science:
- Pharmacology
- Toxicology
- Clinical Medicine
Background:
- Increasing prevalence of synthetic designer drugs with hallucinogenic properties.
- Designer drugs are often chemically modified from existing medications (e.g., for depression, chronic fatigue).
- Widespread availability through internet distributors contributes to accessibility.
Purpose of the Study:
- To review and synthesize current knowledge on clinical symptoms associated with designer drug intoxication.
- To provide insights into appropriate treatment strategies for individuals intoxicated by these substances.
- To highlight the limited understanding of clinical manifestations and management protocols.
Main Methods:
- Systematic review of published literature.
- Inclusion of data from the Danish Poison Centre.
- Analysis of cases involving 284 intoxicated patients.
Main Results:
- Identification of specific clinical symptoms linked to designer drug use.
- Evaluation of treatment outcomes for various intoxication scenarios.
- Data compilation on two chemical derivatives of previously registered drugs.
Conclusions:
- There is a significant knowledge gap regarding the clinical effects and treatment of designer drug intoxication.
- Further research is needed to establish clear diagnostic and therapeutic guidelines.
- Poison control centers play a crucial role in managing cases of designer drug overdose.